Yale Cancer Center

What Yale Cancer Center does

Yale Cancer Center is an NCI-designated Comprehensive Cancer Center, one of only 57 in the United States, operating as a department within Yale School of Medicine in New Haven, Connecticut, and delivering clinical care in collaboration with Smilow Cancer Hospital. Founded in 1974 and continuously NCI-designated for 50 years, the Center offers comprehensive cancer prevention, diagnosis, and treatment services across 13+ disease programs (Brain Tumor, Breast, GI, Gynecologic, Head & Neck, Hematology, Liver, Skin & Kidney, Pediatric, Prostate, Sarcoma, Thoracic, Endocrine) supplemented by specialty programs including Cardio-Oncology, Palliative Care, Psycho-Oncology, Integrative Medicine, and a dedicated Early Onset Cancer Program.

The Center's research infrastructure comprises six research programs (Cancer Immunology, Cancer Prevention & Control, Cancer Signaling Networks, Developmental Therapeutics, Genomics/Genetics/Epigenetics, and DNA Damage and Genome Integrity), three NCI SPORE programs (Skin, Lung, Head/Neck Cancer), specialized centers (DeLuca Center for Hematology, Molecular and Cellular Oncology, Immuno-Oncology), and NCI-funded shared resources (Precision Cancer Modeling, Molecular Assay, RainDrop Digital PCR, Rapid Case Ascertainment). Clinical research operations span more than 500 active trials across 18 cancer categories, supported by AI-powered clinical trial screening (Triomics) and AI-based risk stratification tools (ArteraAI). The Precision Medicine in Cancer Program advances AI applications across the cancer care continuum.

Revenue is generated through clinical services at Smilow Cancer Hospital (insurance/Medicare/Medicaid reimbursement), NCI Cancer Center Support Grant funding, and collaborative pharmaceutical research funding from Genentech, Loxo@Lilly, Gilead Sciences, and Boehringer Ingelheim supporting early-phase trial access. The Center serves cancer patients across Connecticut with targeted outreach to underserved Black and Hispanic populations, operates as an NCCN member institution, and maintains research collaborations with Dana-Farber, Memorial Sloan Kettering, and BioNTech on personalized neoantigen mRNA cancer vaccines.

Name

Yale Cancer Center

Legal name

Yale Cancer Center

Website

https://yalecancercenter.org

Company type

Private

Founded year

1974

Operating status

Operating

Headcount range

11–50 employees

Short description

Yale Cancer Center is an NCI-designated Comprehensive Cancer Center within Yale School of Medicine that delivers cancer diagnosis, treatment, and clinical trials across 13+ disease programs through its collaboration with Smilow Cancer Hospital in New Haven, Connecticut.

Ownership category

akta.pro rank

Product category

Academic Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (62211)

SIC

Services-Health Services (8000), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Thoracic (Lung) Oncology (HLAKAFAL), Neuro-Oncology (HLAKAFAH), Gynecologic Oncology & Women’s Cancer Centers (HLAFAJAK), Oncology & Cancer Specialty Hospitals (HLAFAHAC)

Keywords

• Cancer treatment services
• Clinical research trials
• Oncology care
• Precision medicine
• Academic medical research

Headquarters

HQ city

New Haven

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Clinical Services Revenue: Revenue generated from comprehensive cancer treatment services including chemotherapy, radiation therapy, surgery, and related clinical care delivered at Yale Cancer Center and Smilow Cancer Hospital.
2. Pharmaceutical Research Funding: Collaborative funding from pharmaceutical companies including Genentech, Loxo@Lilly, Gilead Sciences, and Boehringer Ingelheim to support early-phase clinical trials and expand access for underserved populations.
3. NCI Cancer Center Support Grant: National Cancer Institute designated comprehensive cancer center receiving ongoing support grants for cancer research, shared resources, and institutional infrastructure.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Yale Cancer Center is an NCI-designated comprehensive cancer center that delivers integrated cancer prevention, screening, diagnosis, treatment, and clinical research through Yale School of Medicine and Smilow Cancer Hospital. It operates disease-specific treatment programs across 12+ cancer types, runs more than 500 active clinical trials, and supports specialty programs such as precision medicine, cardio-oncology, palliative care, and survivorship care.

Product overview

Yale Cancer Center is a National Cancer Institute (NCI) designated comprehensive cancer center, one of only 57 in the nation, operating as a collaboration between Yale School of Medicine and Smilow Cancer Hospital. The Center offers an integrated portfolio of cancer care services organized across multiple treatment programs (Brain Tumor, Breast, GI, Gynecologic Oncology, Head & Neck, Hematology, Liver, Skin & Kidney, Pediatric, Prostate, Sarcoma, Thoracic), supplemented by specialty programs (Genetics & Prevention, Cardio-Oncology, Integrative Medicine, Palliative Care, Psycho-Oncology, Survivorship). Its research infrastructure comprises five research programs (Cancer Immunology, Prevention & Control, Signaling Networks, Developmental Therapeutics, Genomics & Genetics), three SPORE programs (Skin, Lung, Head & Neck cancers), and shared resources (Precision Cancer Modeling, Molecular Assay, Digital PCR). Clinical research operations span over 18 active trial categories with dedicated teams. The Center also supports precision medicine initiatives incorporating AI-powered clinical trial screening and hosts education/training programs from high school through junior faculty levels.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Treatment Programs and Centers Disease-specific multidisciplinary cancer treatment programs covering brain tumors, breast cancer, endocrine cancers, gastrointestinal cancers, gynecologic oncology, head and neck cancers, hematology, liver cancer, skin and kidney cancer, pediatric oncology, prostate and urologic cancers, sarcoma, and thoracic cancers. Services include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy delivered through Yale School of Medicine and Smilow Cancer Hospital.
• Clinical Research and Trials Active clinical trials across 18 cancer categories (bladder, brain, breast, colorectal, gynecological, head and neck, kidney, leukemia/lymphoma/myeloma, liver, lung, melanoma, pancreas, pediatric, prostate, sarcoma, stomach/esophagus, supportive care, thyroid) with dedicated teams and structured Protocol Review, Data and Safety Monitoring, and Investigator-Initiated Trials Advisory Committees. Patients can enroll to access experimental therapies and early-phase studies.
• Specialty Clinical Programs Specialized patient-facing programs including Cancer Genetics and Prevention, Screening & Prevention, Early Onset Cancer Program, Cardio-Oncology, Integrative Medicine, Interventional Oncology, Ocular Oncology, Onco-Dermatology, Pain Program, Palliative Care, Psycho-Oncology, Sexually Intimacy & Menopause Program, Survivorship Clinic, and Tobacco Treatment. These programs provide complementary care addressing genetic risk, supportive care, quality of life, and survivorship needs.
• Precision Medicine in Cancer Program Program focused on real-world AI applications across the cancer care continuum, from clinical research to population health implementation, including AI in clinical trials, imaging, and oncology care. Incorporates AI-powered clinical trial eligibility screening (via Triomics) and digital pathology risk stratification (via ArteraAI).
• Cancer Education and Training Comprehensive training pipeline spanning high school/undergraduate students, graduate students, medical students (including the Yale Cancer Center Medical Student Clinical Fellowship), postdoctoral associates/fellows, residents, clinical fellows, and junior faculty, including the K12 Calabresi Immuno-Oncology Training Program and ACS CICRT Internship/Post-Baccalaureate Fellows Programs.

Quantifiable outcome

• Zero recurrences among 9 kidney cancer patients in a personalized neoantigen vaccine trial
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• AcurionminorStrategic or Co-development Partner · 17 June 2026Precision oncology company where Yale Cancer Center Director Eric Winer serves on the board and advisory team. Collaboration focuses on advancing OncoGaze AI platform for cancer biomarker detection toward clinical deployment.
• National Comprehensive Cancer Network (NCCN)coreStrategic or Co-development Partner · 20 April 2026NCCN membership and participation in annual conferences. Partnership has resulted in 57 NCCN guideline adaptations for Sub-Saharan Africa and 13 MENA-adapted guidelines, downloaded over 120,000 times.
• Health UniverseminorStrategic or Co-development Partner · 24 March 2026AI technology partner providing keynote speaker Douglas Fridsma at Yale Cancer Center's Precision Medicine in Cancer Program workshop on AI applications in cancer care.
• Mass General BrighamminorStrategic or Co-development Partner · 24 March 2026Healthcare partner providing keynote speaker Danielle Bitterman at Yale Cancer Center's Precision Medicine in Cancer Program workshop covering AI in clinical trials, imaging, and oncology care.
• TriomicscoreTechnology or Integration · 18 November 2025Generative AI company implementing AI-powered clinical-trial screening at Yale Cancer Center and Smilow Cancer Hospital. The system analyzes unstructured medical data and assesses trial eligibility to improve access and efficiency.
• Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 1 November 2025Collaborative research partnership studying hospice enrollment decisions and blood transfusion access for patients with advanced blood cancers. Research published in JAMA Network Open involved 200 participants.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development Partner · 23 April 2025Collaborative research partnership on personalized neoantigen cancer vaccines for kidney and pancreatic cancer. Trial showed promising results with immune responses persisting years after treatment.
• BioNTechcoreStrategic or Co-development Partner · 23 April 2025mRNA technology partner manufacturing personalized neoantigen cancer vaccines for pancreatic cancer patients in clinical trials. Partnership with Genentech for phase trials of mRNA-based therapy.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Memorial Sloan Kettering Cancer Center: Another NCI-designated Comprehensive Cancer Center and active research collaborator with Yale on personalized neoantigen vaccine trials. Directly comparable as a leading academic oncology institution with similar research, clinical trial, and SPORE infrastructure.
• Dana-Farber Cancer Institute: NCI-designated Comprehensive Cancer Center and direct research partner with Yale on hospice/blood cancer studies. Shares the academic cancer center model with parallel clinical trial portfolio and federal research grants.
• MD Anderson Cancer Center: The largest NCI-designated Comprehensive Cancer Center in the U.S. Most directly comparable as a dedicated oncology specialty center with extensive clinical trials, SPORE grants, and translational research programs.
• Fred Hutchinson Cancer Center: NCI-designated Comprehensive Cancer Center with parallel structure in research programs, clinical trials, and academic affiliations. Comparable as a peer academic institution focused on oncology research and treatment.
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center within an academic medical center, comparable in scope of research programs, clinical trial activity, and SPORE funding.
• UCSF Helen Diller Family Comprehensive Cancer Center: NCI-designated Comprehensive Cancer Center operating within a leading academic medical center, comparable in research program structure, clinical trial scale, and precision medicine initiatives.
• Mass General Brigham Cancer Center: Active research collaborator with Yale (keynote participation in Precision Medicine workshops) and an NCI-designated Comprehensive Cancer Center with similar clinical trial and translational research portfolios.
• University of Pennsylvania Abramson Cancer Center: NCI-designated Comprehensive Cancer Center at an academic medical center, directly comparable in research programs, clinical trial infrastructure, and pharma-sponsored early-phase trial activity.
• Stanford Cancer Institute: NCI-designated Comprehensive Cancer Center at Stanford School of Medicine, comparable as an academic oncology center with similar research, training, and clinical trial programs.
• Roswell Park Comprehensive Cancer Center: One of the original NCI-designated Comprehensive Cancer Centers, providing a direct structural peer with similar scope of research, clinical trials, and specialty oncology programs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/YaleCancer
• YouTubeyoutube.com/c/YaleCancerCenter
• Facebookfacebook.com/YaleCancerCenter
• LinkedInlinkedin.com/company/yale-cancer-ctr
• Instagraminstagram.com/SmilowCancerHospital

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yale Cancer Center